ArticlePatient education and counseling2026
Women's screening preferences shift after being informed about the 2024 USPSTF breast cancer screening guideline.
Article in Patient education and counseling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Association of Stroke and Myocardial Infarction Symptom Knowledge with Cancer Screening Participation Among Patients with Hypertension and Diabetes: A Cross-Sectional Study in Korea.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionIn 2024 the United States Preventive Services Task Force (USPSTF) revised its breast cancer screening (BCS) guidelines to recommend that all women screen biennially from age 40-74, replacing its prior recommendation that women ages 40-49 engage in informed decision-making about when to begin BCS. We examined how communicating information about the new guideline influenced women's screening preferences and views on what information women should receive before screening.
methodsThis study included 301 women who were previously enrolled in a longitudinal study where they were exposed to a decision aid informing them about BCS harms and benefits and the prior USPSTF recommendation. Participants completed an online survey including an informational intervention that presented information about the 2024 USPSTF recommendation. Outcomes included screening preferences pre- and post-intervention and ratings (1 =not at all important to 4 =very important) of information considered important to know before screening.
resultsInformation about the new guideline influenced participants' screening preferences. Post-intervention, compared with pre-intervention, participants preferred to screen at their current age (86% vs 81%; p < 0.001) and biennially thereafter (45% vs 33%; p < 0.001). Participants believed it was important for women to be informed about the benefits of screening (M=3.77), their personal risk of breast cancer (M=3.75), and about overdiagnosis (M=3.48) and false positives (M=3.61).
conclusionsBeing informed about the 2024 USPSTF mammography guidelines shifted screening preferences to be consistent with the new guideline. Even though the new guideline deemphasizes informed decision-making, women still wanted to be informed about BCS harms and benefits, as well as their personal cancer risk. PRACTICE IMPLICATIONS: Clinicians and health systems may consider pairing clear and directive information about the new BCS guidelines with brief information about BCS benefits and harms and personal risk, to support guideline-concordant and informed screening decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.